Contineum Therapeutics (CTNM) Depreciation & Amortization (CF) (2023 - 2026)
Contineum Therapeutics (CTNM) posted quarterly Depreciation & Amortization (CF) of $134000.0 for Q2 2026, up 69.62% year-over-year from $79000.0 in Q2 2025, and up 61.45% quarter-over-quarter from $83000.0 in Q1 2026.
Powered by 
Analysis
Contineum Therapeutics (CTNM) Depreciation & Amortization (CF) (2023 - 2026) Analysis & Trends
Contineum Therapeutics' Depreciation & Amortization (CF) history runs 4 years deep, the most recent figure standing at $134000.0 for Q2 2026.
- In Q2 2026, Depreciation & Amortization (CF) rose 69.62% year-over-year to $134000.0; the TTM figure through Jun 2026 stood at $383000.0 (up 13.99% YoY), while the FY2025 annual figure was $323000.0, up 7.67% from the prior year.
- Depreciation & Amortization (CF) for Q2 2026 stood at $134000.0, up from $83000.0 in the prior quarter.
- The five-year high for Depreciation & Amortization (CF) was $134000.0 in Q2 2026, with the low at $42000.0 in Q2 2023.
- The 4-year median for Depreciation & Amortization (CF) is $75500.0 (2023), against an average of $74285.7.
- The sharpest annual moves came in 2024 and 2025: Depreciation & Amortization (CF) jumped 178.57% in 2024, then retreated 27.35% in 2025.
- Contineum Therapeutics' Depreciation & Amortization (CF) stood at $42000.0 in 2023, then surged by 178.57% to $117000.0 in 2024, then declined by 27.35% to $85000.0 in 2025, then surged by 57.65% to $134000.0 in 2026.
- Business Quant data shows CTNM's Depreciation & Amortization (CF) at $134000.0 in Q2 2026, $83000.0 in Q1 2026, and $85000.0 in Q4 2025.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Depreciation & Amortization (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.43 Bn | 130.58 Bn | 2.84 Bn | 56.50 Mn |
| 2 | Regeneron Pharmaceuticals | 85.18 Bn | 77.19 Bn | 3.93 Bn | 123.70 Mn |
| 3 | Argenx Se | 63.34 Bn | 58.15 Bn | 1.37 Bn | - |
| 4 | Moderna | 57.98 Bn | 52.85 Bn | 52.00 Mn | - |
| 5 | Revolution Medicines | 43.98 Bn | 43.98 Bn | - | - |
| 6 | BeOne Medicines | 39.92 Bn | 34.82 Bn | 1.53 Bn | 40.52 Mn |
| 7 | Alnylam Pharmaceuticals | 35.42 Bn | 32.11 Bn | 992.69 Mn | - |
| 8 | Royalty Pharma | 28.42 Bn | 27.58 Bn | - | - |
| 9 | Insmed | 27.36 Bn | 26.20 Bn | 358.27 Mn | - |
| 10 | Contineum Therapeutics | 628.34 Mn | 628.34 Mn | - | 134,000.00 |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | 134,000.00 |
| Mar 31, 2026 | 83,000.00 |
| Dec 31, 2025 | 85,000.00 |
| Sep 30, 2025 | 81,000.00 |
| Jun 30, 2025 | 79,000.00 |
| Mar 31, 2025 | 78,000.00 |
| Dec 31, 2024 | 117,000.00 |
| Sep 30, 2024 | 62,000.00 |
| Jun 30, 2024 | 60,000.00 |
| Mar 31, 2024 | 61,000.00 |
| Dec 31, 2023 | 42,000.00 |
| Sep 30, 2023 | 43,000.00 |
| Jun 30, 2023 | 42,000.00 |
| Mar 31, 2023 | 73,000.00 |